Martin Pool Selected Research

Martin Pool Research Topics

9	Neoplasms (Cancer) 01/2023 - 08/2015
2	Breast Neoplasms (Breast Cancer) 01/2023 - 11/2017
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 08/2017 - 07/2017
1	Neoplasm Metastasis (Metastasis) 01/2023
1	Residual Neoplasm 01/2023
1	Margins of Excision 01/2023
1	Thyroid Neoplasms (Thyroid Cancer) 12/2022
1	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2022
1	B-Cell Lymphoma (Lymphoma, B Cell) 01/2022
1	Lung Neoplasms (Lung Cancer) 01/2019
1	Leukemia 01/2016
1	Bites and Stings (Sting) 01/2016
1	Colorectal Neoplasms (Colorectal Cancer) 01/2016
1	Squamous Cell Neoplasms (Squamous Cell Cancer) 01/2016

5	ErbB Receptors (EGF Receptor)IBA 01/2019 - 08/2015
3	Tyrosine Kinase InhibitorsIBA 12/2022 - 08/2017
2	Fluorescent Dyes (Fluorescent Probes)IBA 01/2023 - 01/2016
2	Proteins (Proteins, Gene)FDA Link 01/2022 - 11/2017
2	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2019 - 08/2017
2	Monoclonal AntibodiesIBA 07/2017 - 10/2016
2	Cetuximab (Erbitux)FDA Link 07/2017 - 08/2015
2	IRDye 800CWIBA 01/2016 - 08/2015
1	CathepsinsIBA 01/2023
1	Cysteine (L-Cysteine)FDA Link 01/2023
1	lenvatinibIBA 12/2022
1	Immunoglobulin G (IgG)IBA 01/2022
1	Immunoconjugates (Immunoconjugate)IBA 01/2022
1	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidIBA 01/2022
1	Pentetic Acid (DTPA)FDA LinkGeneric 01/2022
1	Zirconium-89IBA 11/2017
1	Lapatinib (GW572016)FDA Link 11/2017
1	human ERBB2 proteinIBA 11/2017
1	LigandsIBA 08/2017
1	onartuzumabIBA 08/2017
1	Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA 08/2017
1	imgatuzumabIBA 07/2017
1	Epithelial Cell Adhesion MoleculeIBA 01/2016
1	pertuzumabIBA 08/2015
1	Epidermal Growth Factor (EGF)IBA 08/2015

2	Therapeutics 12/2022 - 01/2019
1	Segmental Mastectomy (Lumpectomy) 01/2023
1	Radiotherapy 01/2023
1	Drug Tapering 12/2022
1	Radioimmunotherapy 01/2022
1	Intravenous Administration 01/2016